Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
258 hedge funds and large institutions have $4.58B invested in Verona Pharma in 2025 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 71 increasing their positions, 86 reducing their positions, and 15 closing their positions.
473% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $3.19B → $4.58B (+$1.39B)
35% more funds holding
Funds holding: 191 → 258 (+67)
22% more funds holding in top 10
Funds holding in top 10: 23 → 28 (+5)
0.93% more ownership
Funds ownership: 10.48% → 11.41% (+0.93%)
17% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 86
51% less call options, than puts
Call options by funds: $70.5M | Put options by funds: $144M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$230M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$186M |
| 3 |
Holocene Advisors
New York
|
+$81.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$77.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$64.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$173M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$82.1M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$80.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$60.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$53.5M |
VRNA Hedge Fund Activity: Q1 2025 in Review
258 of the 7,430 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2025, worth a combined $4.58B — up 44% from $3.19B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new VRNA positions and 15 closed out — a net gain of 71 holders — while 71 added to existing stakes and 86 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $230M. The largest seller was NEA Management Company, cutting an estimated $173M.
- 258 institutional investors held Verona Pharma (VRNA) as of Q1 2025, up from 191 in Q4 2024.
- Funds reported $4.58B of Verona Pharma stock for Q1 2025, up 44% quarter-over-quarter.
- 86 funds opened new Verona Pharma positions in Q1 2025 and 15 closed out, a net change of +71 holders.
- The largest Verona Pharma buyer in Q1 2025 was Janus Henderson Group, an estimated $230M added.
- The largest Verona Pharma seller in Q1 2025 was NEA Management Company, an estimated $173M sold.
Based on aggregated 13F filings for Q1 2025.